Nuvaxovid™ is the first protein-based COVID-19 vaccine available for use in adolescents aged 12 through 17 in Australia Preliminary safety data from the trial showed the vaccine to be generally ...

Vasso Apostolopoulos COVID-19 research has received internal funding from Victoria University place-based Planetary Health research grant and from philanthropic donations. Jack Feehan does not work ...

In Australia, Nuvaxovid™ is the first protein-based COVID-19 vaccine registered for use as a booster regardless of previous vaccine history GAITHERSBURG, Md., June 13, 2022 /PRNewswire/ -- Novavax, ...

(RTTNews) - Novavax, Inc. (NVAX) announced the Australian Therapeutic Goods Administration has granted provisional registration of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine as a booster in individuals ...

Lots of people are hearing about Novavax, the fourth COVID vaccine option in the U.S., for the first time, but it’s been authorized for use as a primary vaccine series since early 2022. Previously, it ...

Novavax requested U.S. EUA of its COVID-19 vaccine on Jan. 31, 2022, but the FDA still hasn't made a decision. The FDA does appear to be taking its time with the review -- probably because it doesn't ...

Nov 4 (Reuters) - Novavax Inc (NVAX.O), opens new tab said on Wednesday it has signed an agreement with the Australian government to supply 40 million doses of its COVID-19 vaccine candidate, ...

Since their debut just 18 months ago, three COVID-19 vaccines have saved an estimated 2.2 million American lives, changed the trajectory of a pandemic and inspired all manner of conspiracy theories.

U.S. adults who haven't gotten any COVID-19 shots yet should consider a new option from Novavax — a more traditional kind of vaccine, health officials said Tuesday. Regulators authorized the nation's ...

Nuvaxovid™ is the first protein-based COVID-19 vaccine available for use in adolescents aged 12 through 17 in Australia GAITHERSBURG, Md., July 26, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a ...